Researchers developed a CAR-T manufacturing strategy using the cytokine fusion scaffold HCW9206 to generate longer-lasting ...

Results from the phase 3 RECITE trial show that romiplostim significantly reduces chemotherapy-induced thrombocytopenia, ...

A Nature Cell Biology study shows that vitamin B2 metabolism helps cancer cells evade ferroptosis by stabilizing ferroptosis ...

New findings from the phase III PRIMARY2 trial presented at EAU26 suggest that PSMA PET/CT imaging after inconclusive or reassuring MRI can safely reduce prostate biopsies by about 50 percent without ...

A nationwide U.S. study published in JAMA, analyzing data from 2.15 million women with breast cancer, found that choosing complementary and alternative medicine (CAM) instead of evidence-based therapy ...

ONCOLife as a cutting-edge oncology magazine designed for oncologists and health professionals. It has flexible format, available both in print and online formats in the US and EU, ONCOLife is ...

GSK’s B7-H3 targeted antibody drug conjugate risvutatug rezetecan has received FDA Orphan Drug Designation for small cell lung cancer, supported by early ARTEMIS 001 data showing durable responses in ...

BioNTech SE and Bristol Myers Squibb have partnered to co-develop and co-commercialize BNT327, a next-generation bispecific antibody targeting PD-L1 and VEGF-A in over 10 solid tumor indications. The ...

The U.S. Food and Drug Administration (FDA) has approved the PD-1 inhibitor Libtayo® (cemiplimab-rwlc) as the first and only immunotherapy for the adjuvant treatment of cutaneous squamous cell ...

Oncolytic viruses are a very promising class of therapeutic agents, with a broad range of types. They not only infect and kill cancer cells, but also modulate the tumor micro-environment to enhance ...

FDA has approved AKEEGA (niraparib and abiraterone) as the first precision therapy for BRCA2+ metastatic castration-sensitive prostate cancer (mCSPC), following results from the Phase 3 AMPLITUDE ...